Ravidasvir

Ravidasvir is an antiviral drug used in the treatment of Hepatitis C. It is a direct-acting antiviral agent (DAA) and specifically targets the NS5A protein, which is essential for the replication of the Hepatitis C virus. Ravidasvir is often used in combination with other antiviral drugs to increase the effectiveness of treatment.

Mechanism of Action[edit | edit source]

Ravidasvir inhibits the NS5A protein, a phosphoprotein that plays a crucial role in the replication of the Hepatitis C virus. By binding to this protein, Ravidasvir prevents the virus from replicating and spreading within the body.

Clinical Use[edit | edit source]

Ravidasvir has been used in combination with other antiviral drugs such as Sofosbuvir to treat Hepatitis C. This combination has shown high cure rates in clinical trials, even in patients with advanced liver disease or those who have previously failed other treatments.

Side Effects[edit | edit source]

Like all medications, Ravidasvir can cause side effects. The most common side effects include fatigue, headache, and nausea. However, these side effects are usually mild and go away on their own.

Development and Approval[edit | edit source]

Ravidasvir was developed by Presidio Pharmaceuticals, a biopharmaceutical company based in San Francisco, California. It was later licensed to Pharco Pharmaceuticals, an Egyptian company, for production and distribution in certain countries.

In 2018, the World Health Organization prequalified Ravidasvir, making it more accessible for low- and middle-income countries.